Therefore, the outcomes of HVEM interactions with BTLA or LIGHT within the TME are dichotomous: the BTLA-HVEM interaction promotes immune suppression and tumor progression, while the LIGHT-HVEM interaction drives immune activation and antitumor immunity. The gene discussed is TNFSF14; the disease is neoplasm.